A clinical trail being undertaken by Monash is promising to restore the libido for as much as 30 per cent of women in Australia who struggle to reach orgasm.

 

The trial promises to treat anorgasmia, one of the most common female sexual complaints, which is either a life-long problem or acquired, and afflicts as much as one third of women.

 

Researchers at Monash University, led by Professor Susan Davis of the Women’s Health Group, are testing the effectiveness of a testosterone-based ‘as required’ treatment.

 

"We anticipate the treatment will work like Viagra for women. Rather than a long-term, therapy-based approach, this drug can be taken when a woman anticipates sexual activity," Professor Davis said.


"We have previously shown that for women with low sexual interest, testosterone therapy not only improves sexual desire and arousal, but also enhances a woman’s ability to reach orgasm. 


The treatment would be administered in droplet sized doses via the nostrils and will be effective from two hours after it is administered, for up to six hours. With both neurological and vascular effects, it is anticipated the drug will be effective in the context of sexual activity, but will have no ill-effects if the activity doesn't take place.

 

The researchers are hoping to recruit pre-menopausal women from Melbourne, Sydney, Perth and Adelaide to take part in the trial. Participants must be aged 18 to 49 and have experienced anorgasmia.



The trial is also taking place in the US and Canada. The research is supported by Trimel Biopharma SRL Canada, which developed the drug.


Those interested in participating in the trial should call 1800 998 055.